Syndax: Two Commercial Launches Set Up a Clear Revenue Trajectory — Tactical Long
Syndax has moved from early commercial teething pains to generating real top-line traction: $172.4M in trailing annual revenue versus $23.7M the prior year. With two approved oncology drugs now in market and distribution expansion underway, the stock offers an asymmetric trade: near-term operational execution risk but meaningful upside if adoption …